Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, November 29 2022 - 19:06
Probiotic strain SNZ 1969(R) helps manage IBS-D & IBS-C symptoms effectively, latest clinical study shows
HYDERABAD, India, Nov. 29, 2022 /PRNewswire-Asianet/ --

    Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 
1969(R)(Weizmannia coagulans SNZ 1969), a natural spore forming probiotic 
strain over five decades of use and more than 30 human studies across age 
groups found to be effective in managing IBS symptoms. This study is unique as 
it covers both the IBS-Diarrhea and IBS-Constipation groups with larger number 
of subjects.

    Irritable bowel syndrome (IBS) is one of the most common disorders of 
gut-brain interaction, estimated to affect around 11% people globally. The 
outcome of this study will be significant to supplement manufacturers as it can 
help design products to address consumer need for managing IBS symptoms with a 
scientifically studied probiotic strain. Several factors, such as the 
increasing fear of antibiotic resistance, the increasing demand of consumers 
for natural substitutes for drugs, and the emergence of scientific and clinical 
evidence showing the efficacy of probiotics, have contributed to many health 
professionals considering probiotics as an alternative to drug remedies. 

    In a randomized, double blind, placebo-controlled study, probiotic 
potential of SNZ 1969(R) has been studied in subjects with constipation 
predominant irritable bowel syndrome (IBS-C) and diarrhea predominant irritable 
bowel syndrome (IBS-D). Significant reduction in GSRS IBS score was seen in 
both the treatment group compared to placebo (P <0.0001). SNZ 1969® was 
well-tolerated and showed significant alleviation of IBS-associated clinical 
symptoms compared to placebo and improved the Quality of Life of IBS patients

    This study was conducted at Apollo Hospitals, Hyderabad, India and 
published in the International Journal of Basic & Clinical Pharmacology.

    The same strain has been studied earlier for gastrointestinal discomfort, 
intestinal motility and intermittent constipation among healthy subjects. GI 
discomfort study showed an improvement in total SODA scores, including specific 
symptoms such as burping/belching, bloating, heartburn, passing gas, nausea, 
bad breath, and sour taste compared with placebo. Intestinal motility study 
concluded that SNZ 1969(R) reaches the colon intact and ameliorates intestinal 
motility and gut microbiota composition.

    Sanzyme Biologics was incorporated in 1969 as Uni-Sankyo. Over the last 
five decades Sanzyme Biologics established its strength in probiotics by 
developing scientifically studied and well-documented probiotic strains, 
pioneered their applications beyond human health into aqua, veterinary, poultry 
and bioremediation. Sanzyme Biologics has market presence in over 40 countries. 

    To know more, visit or contact Ph: +91-40-48589999


    Source: Sanzyme Biologics